Systems-Informed prioritization of Exosomal Protein Candidates in TNBC Identifies an ECM Invasion Module and Nominates Agrin as a High-Priority Target

BackgroundTriple-negative breast cancer (TNBC) remains the most clinically challenging breast cancer subtype, in part due to the absence of validated molecular targets and the limited availability of non-invasive early detection strategies. Tumor-derived exosomes have emerged as promising liquid biopsy analytes, yet the functional organization of their protein cargo and the identification of biologically meaningful candidates remain incompletely characterized. MethodsWe present a Composite Driver Score (CDS) framework that integrates differential expression magnitude with protein-protein interaction network topology and Analytic Hierarchy Process (AHP)-based multi-criteria weighting to prioritize exosomal protein candidates in a systems-informed manner. The framework was applied to publicly available label-free quantitative proteomic datasets comparing MDA-MB-231 (TNBC) and MCF-10A (non-tumorigenic) exosomal fractions, with cross-dataset validation performed on an independent proteomic dataset. ResultsCDS prioritization demonstrated robustness to variations in proteome depth and parameter weighting, consistently recovering a functionally coherent set of extracellular matrix (ECM) and adhesion-associated proteins. Network and pathway analyses revealed coordinated co-enrichment of integrin receptors, cognate ECM ligands, and associated co-receptors -- consistent with selective packaging of a functionally integrated invasion module. Agrin (AGRN), a heparan sulfate proteoglycan with virtually limited prior characterization in TNBC exosome biology, emerged as a high-priority candidate through its network integration within this ECM program. ConclusionsThese findings support a model in which TNBC-derived exosomes carry coordinated molecular programs capable of modulating extracellular matrix architecture. The CDS framework offers a transferable strategy for integrative exosomal biomarker prioritization and a systems-level foundation for targeted liquid biopsy panel development.